Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.

(i.e., difference of 753 nM∙h/day) was associated with a lower likelihood of IRC‐assessed response that did not reach statistical significance (OR: 0.778, 95% CI: 0.550–1.10, P = 0.156; Table 2 ).

also in 111,027 other papers